10 Summer Activities: What's the COVID-19 Risk?

Slideshow

Experts in infectious disease rate a wide range of summer activities as low, medium, or high COVID-19 risk. When your patients ask, you'll be ready.

COVID-19 has kept people around the world at home for 2 months. The yearning to do something "normal" is real--and it's everywhere. But what is safe and how safe? Recently NPR Shots asked a panel of infectious disease and public health experts to rate the risk of summer activities, from backyard gatherings to a day at the pool to staying in a hotel.

We chose 10 of those activities for this slide show. Your patients may have already started asking about them. Here is what experts advise.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years

FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years

Sydney Jennings
July 10th 2025
Article

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Image courtesy of Cincinnati Children's

Intranasal COVID-19 Vaccine Found Safe and Immunogenic in Open Label Phase 1 Clinical Trial

Grace Halsey
July 7th 2025
Article

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

Sydney Jennings
October 25th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.

Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned / image credit ©Rafael Henrique/stock.adobe.com

Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned

Grace Halsey
June 2nd 2025
Article

Kennedy over 2 weeks has introduced changes in vaccination recommendations and research policy that undermine already tenuous public trust and understanding.

FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines / Image credit: ©Tada Images/AdobeStock

FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines

Sydney Jennings
May 27th 2025
Article

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

© 2025 MJH Life Sciences

All rights reserved.